Synlogic Inc., of Cambridge, Mass., said preclinical data published in Nature Biotechnology show that SYNB-1618, its Synthetic Biotic program targeting phenylketonuria (PKU), significantly reduced blood phenylalanine levels, the key metabolite associated with PKU, in mouse models, and resulted in dose-dependent pharmacodynamics in healthy nonhuman primates. SYNB-1618 currently is in phase I/IIa testing.